Natriuretic Peptide-based Screening and Prevention of Heart Failure

Joe Gallagher, Chris Watson, Patricia Campbell, Mark Ledwidge, Kenneth McDonald

Research output: Contribution to journalArticlepeer-review


There is increasing interest in the concept of personalised medicine, whereby conditions with common pathophysiologies are targeted together, and also using biomarkers to identify patients who will most benefit from certain interventions. Several data sets indicate that natriuretic peptides are effective in refining risk prediction for heart failure and cardiovascular disease and add predictive power to conventional risk factors. To date two trials have tested the approach of using natriuretic peptides as part of a strategy to identify those at highest risk of cardiovascular events: St. Vincent's Screening to Prevent Heart Failure (STOP-HF) and N-terminal Pro-brain Natriuretic Peptide Guided Primary Prevention of Cardiovascular Events in Diabetic Patients (PONTIAC). These have shown natriuretic peptide-based screening and targeted prevention can reduce heart failure and left ventricular dysfunction and other major cardiovascular events. This approach is now part of North American guidelines.

Original languageEnglish
Pages (from-to)83-85
JournalCardiac Failure Review
Issue number2
Publication statusPublished - 01 Nov 2017


  • Journal Article


Dive into the research topics of 'Natriuretic Peptide-based Screening and Prevention of Heart Failure'. Together they form a unique fingerprint.

Cite this